[1] Venkataramana K.Sidhaye,Kristine Nishida,Fernando J.Martinez.Precision medicine in COPD: where are we and where do we need to go? [J]. Eur Respir Rev, 2018, 27(149): 180022.
[2] Antonino Di Stefano,Teresa Coccini,Elisa Roda,et al.Blood MCP-1 levels are increased in chronic obstructive pulmonary disease patients with prevalent emphysema [J]. International Journal of Chronic Obstructive Pulmonary Disease, 2018, 13:1691-700.
[3] Martinez FJ,Han MK,Allinson JP,et al.At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease [J]. American Journal of Respiratory and Critical Care Medicine, 2018, 197(12): 1540-51.
[4] Miravitlles M,Soler-Cataluña JJ,Calle M,et al. Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease(GesEPOC)2017.Pharmacological Treatment of Stable Phase [J]. Arch Bronconeumol, 2017, 53(6): 324-35.
[5] Jian-Jun Wu, Hong-Ri Xu, Ying-Xue Zhang,et al. The Characteristics of the Frequent Exacerbators With Chronic Bronchitis Phenotype and the Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome Phenotype in Chronic Obstructive Pulmonary Disease Patients: A Meta-Analysis and System Review[J]. Medicine (Baltimore), 2019, 98(46): e17996.
[6] Kania A,Krenke R,Kuziemski K,et al. Distribution and characteristics of COPD phenotypes-results from the Polish sub-cohort of the POPE study [J]. International Journal of Chronic Obstructive Pulmonary Disease, 2018, 13:1613-21.
[7] Reiger G,Zwick R,Lamprecht B,et al. Phenotypes of COPD in an Austrian population: National data from the POPE study [J]. Wiener Klinische Wochenschrift, 2018, 130(11-12): 382-9.
[8] Alcázar-Navarrete Bernardino,Trigueros Juan Antonio,Riesco Juan Antonio,et al. Geographic variations of the prevalence and distribution of COPD phenotypes in Spain: “the ESPIRAL-ES study” [J]. Oxidative Medicine and Cellular Longevity, 2018, 13:1115-24.
[9] Alcázar-Navarrete B,Romero-Palacios PJ,Ruiz-Sancho A,et al. Diagnostic performance of the measurement of nitric oxide in exhaled air in the diagnosis of COPD phenotypes [J]. Nitric Oxide - Biology and Chemistry, 2016, 54:67-72.
[10] Alexandru Corlateanu,Victor Botnaru,Doina Rusu, et al. Assessment of health-related quality of life in different phenotypes of COPD [J]. Current Respiratory Medicine Reviews, 2017, 13(2): 105-9.
[11] Cosio BG,Soriano JB,López-Campos JL,et al. Correction: Distribution and Outcomes of a Phenotype-Based Approach to Guide COPD Management: Results from the CHAIN Cohort [J]. PLoS ONE, 2016, 11 (9):e0160770.
[12] Golpe R,Suárez-Valor M,Martín-Robles I,et al. Mortality in COPD patients according to clinical phenotypes [J]. International Journal of Chronic Obstructive Pulmonary Disease, 2018, 13:1433-9.
[13] Koblizek V,Milenkovic B,Barczyk A,et al. Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE Study [J]. The European Respiratory Journal, 2017, 49(5):1601446.
[14] Miravitlles M,Barrecheguren M,Román-Rodríguez M. Frequency and characteristics of different clinical phenotypes of chronic obstructive pulmonary disease [J]. International Journal of Tuberculosis and Lung Disease, 2015, 19(8): 992-8.
[15] Arkhipov V,Arkhipova D,Miravitlles M,et al. Characteristics of COPD patients according to GOLD classification and clinical phenotypes in the Russian Federation: the SUPPORT trial [J]. International Journal of Chronic Obstructive Pulmonary Disease, 2017, 12:3255-62.
[16] Chee-Shee Chai,Chong-Kin Liam,Yong-Kek Pang,et al. Clinical phenotypes of COPD and health-related quality of life: a cross-sectional study [J]. International Journal of COPD, 2019, 14:565-73.
[17] Pan Qing,Lv Zhifang.clinical application value of the new guide patients with chronic obstructive pulmonary disease. [J]. Journal of shandong university(health sciences), 2016, 54(3): 63-7.
[18] Calle Rubio M,Casamor R,Miravitlles M. Identification and distribution of COPD phenotypes in clinical practice according to Spanish COPD Guidelines: the FENEPOC study [J]. International Journal of Chronic Obstructive Pulmonary Disease, 2017, 12:2373-83.
[19] Begg CB,Mazumdar M. Operating characteristics of a rank correlation test for publication bias [J]. Biometrics, 1994, 50(4): 1088-101.
[20] Harbord RM,Egger M,Sterne JA. A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints [J]. Stat Med, 2006, 25(20): 3443-57.
[21] Windisch W,Criée CP.COPD-Importance of Lung Function Testing for Diagnosis and Treatment[J].Dtsch Med Wochenschr.2018,143(8):593-596.
[22] Lei Zhu,Lijuan Hu,Li li,et al. Suggestions on diagnosis of pulmonary function [J]. Chin J Tubere Respir Dis, 2018, 41(4): 308-11.
[23] Augustin IML,Wouters EFM,Houben-Wilke S,et al. Comprehensive Lung Function Assessment Does not Allow to Infer Response to Pulmonary Rehabilitation in Patients with COPD. [J]. J Clin Med, 2019, 8(1): pii:E27.
[24] GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2018. ; 2018 (https://goldcoped.org/. Accessed July 17, 2018).
[25] Umur Hatipoğlu. Chronic obstructive pulmonary disease:More than meets the eye [J]. Annals of Thoracic Medicine, 2018, 13(1): 1-6.
[26] Magnus MC1,Henderson J,Tilling K,et al. Independent and combined associations of maternal and own smoking with adult lung function and COPD [J]. Int J Epidemiol, 2018, 47(6): 1855-64.
[27] Cheng SL,Lin CH,Wang CC,et al. Comparison between COPD Assessment Test (CAT) and modified Medical Research Council (mMRC) dyspnea scores for evaluation of clinical symptoms, comorbidities and medical resources utilization in COPD patients [J]. J Formos Med Assoc, 2019, 118(1 Pt 3): 429-35.
[28] Grigsby MR1,Siddharthan T,Pollard SL,et al. Low Body Mass Index Is Associated with Higher Odds of COPD and Lower Lung Function in Low- and Middle-Income Countries [J]. Copd, 2019, 16(1) 58-65.
[29] Mansoor S, Obaida Z, Ballowe L,,et al. Clinical Impact of Multidisciplinary Outpatient Care on Outcomes of Patients with COPD [J]. Int J Chron Obstruct Pulmon Dis, 2020, 15: 33-42.
[30] Guerreiro I, Soccal PM. COPD and phenotypes [J]. Rev Med Suisse, 2019, 15(671): 2082-2086.
[31] Pikoula M, Quint JK, Nissen F,et al. Identifying clinically important COPD sub-types using data-driven approaches in primary care population based electronic health records [J]. BMC Med Inform Decis Mak, 2019, 19(1): 86.
[32] Radovanovic D, Contoli M, Marco FD, et al. Clinical and Functional Characteristics of COPD Patients Across GOLD Classifications: Results of a Multicenter Observational Study [J]. COPD, 2019, 16(3-4): 215-226.
[33] Jo YS, Kim SK, Park SJ, et al. Longitudinal change of FEV1 and inspiratory capacity: clinical implication and relevance to exacerbation risk in patients with COPD [J]. Int J Chron Obstruct Pulmon Dis. 2019, 14: 361-369.